The benefits of the fully human monoclonal antibody secukinumab at doses of either 150 or 300 mg weekly in patients with active psoriatic arthritis are sustained even after 4 years, according to updated results of the FUTURE 2* study presented at the Inflammatory Skin Disease Summit (ISDS 2018).
Treatment with risankizumab, an interleukin-23 inhibitor, significantly improves skin appearance in patients with moderate-to-severe plaque psoriasis, according to the IMMvent* study presented at the Inflammatory Skin Disease Summit (ISDS).
Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
The human monoclonal antibody tralokinumab significantly reduced skin colonization by Staphylococcus aureus (S. aureus) in adults with moderate-to-severe atopic dermatitis (AD), according to a study presented at ISDS 2018.
The non-steroidal phosphodiesterase-4 inhibitor crisaborole may reduce lesions in patients with mild-to-moderate atopic dermatitis (AD), according to an intrapatient randomized study presented at the Inflammatory Skin Disease Summit (ISDS) 2018.
Treatment with the human monoclonal antibody dupilumab led to improved asthma and sinonasal outcomes occurring concurrently with atopic dermatitis (AD), according to the results of a pooled analysis of four phase 3 trials* presented at ISDS 2018.
Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.
Patients with atopic dermatitis (AD) have elevated levels of sodium chloride or salt in their skin compared with those with nonlesional atopic and healthy skin, according to a new study finding which experts described as “provocative.”